Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
The last several months have marked a true inflection point for ImmuCell. This transition began...
— Sean Kirkwood
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on ImmuCell Corporation
ImmuCell is a $65mm market cap animal health company whose core franchise is the First Defense line of products, which protect newborn calves against scours, a leading cause of death for young calves.
ImmuCell Corporation ($ICCC) is an animal health company focused on developing and commercializing preventative biological products, led by its flagship First Defense franchise that treats calf scours (severe neonatal diarrhea in dairy and beef calves). The manager's bullish...
More institutional theses from SRK Capital
The fund completely exited its position in Harrow after recognizing that execution risks and excessive market optimism were priced into the stock during its price surge. Capital was recycled...
Heritage Global faced temporary Q3 noise from a specialty lending credit loss reserve, but macro credit card charge-off trends strongly favor its core brokerage segment. The post-earnings decline...
Innovative Solutions & Support offers ~20% organic growth supplemented by a high-return bolt-on acquisition strategy that leverages unutilized manufacturing capacity. Its recent acquisition...